RecruitingPhase 1NCT05720117

A Study of PYX-201 in Advanced Solid Tumors

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors

Sponsor

Pyxis Oncology, Inc

Enrollment

330 participants

Start Date

Mar 14, 2023

Study Type

INTERVENTIONAL

Conditions

Solid Tumor Advanced Solid Tumor

Summary

The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called PYX-201 for people with advanced solid tumor and solid tumor. The study is currently recruiting participants at 29 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPYX-201

Antibody-Drug Conjugate

Locations(29)

HonorHealth Research Institute

Scottsdale, Arizona, United States

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

SCRI - HealthOne Denver

Denver, Colorado, United States

SCRI - Florida Cancer Specialists

Sarasota, Florida, United States

Winship Cancer Institute, Emory University

Atlanta, Georgia, United States

University of Chicago Medicine

Chicago, Illinois, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Washington University School of Medicine

St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

University of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, United States

Rhode Island Hospital

Providence, Rhode Island, United States

NEXT Dallas

Dallas, Texas, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

NEXT San Antonio

San Antonio, Texas, United States

NEXT Virginia

Fairfax, Virginia, United States

Institut Jules Bordet

Brussels, Brussels Capital, Belgium

Cliniques Universitaires Saint-Luc

Brussels, Brussels Capital, Belgium

Universitair Ziekenhuis Antwerpen

Edegem, Edegem, Belgium

Universitair Ziekenhuis Gent

Ghent, Gent, Belgium

Hospital Universitari Vall d'Hebrón

Barcelona, Barcelona, Spain

START Madrid - Hospital Universitario Fundación Jiménez Díaz

Madrid, Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Madrid, Spain

Hospital Universitario HM Sanchinarro

Madrid, Madrid, Spain

Hospital Clínico Universitario de Valencia

Valencia, València, Spain

University College Hospital

London, England, United Kingdom

The Royal Marsden Hospital

London, England, United Kingdom

Sarah Cannon Research Institute London

London, England, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05720117

Related Trials

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

NCT063984181 location

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

NCT065633751 location

Study of D3L-002 in Subjects With Advanced Solid Tumors

NCT07667842

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT0526762618 locations